Windtree Therapeutics' investigational drug istaroxime, being developed as a potential treatment for acute heart failure with reduced ejection fraction, received fast-track designation from the FDA this month based on results from its Phase IIb trial that showed the drug, injected intravenously, improved cardiac function in patients while also facilitating myocardial relaxation.
Fast-track status granted to Windtree's istaroxime for acute HFrEF
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.